SLC18A2 and thanatophoric dysplasia: Currently, Vesicular Monoamine Transporter 2 (VMAT2) inhibitors such as Tetrabenazine, Valbenazine, and Deutetrabenazine are available for the treatment of TD [30, 31, 32].